sulodexide药理的状况。

文章的细节

引用

复制到剪贴板

Hoppensteadt哒,法里德·J

sulodexide药理的状况。

Int Angiol。2014年6月,33 (3):229 - 35。

PubMed ID

24936531 (在PubMed

]

文摘

sulodexide自推出以来,一直在使用和关闭几个迹象。最近这个代理已经成为充满活力和测试新的适应症。Sulodexide由粘多糖,包括快速肝素和硫酸dermatan的混合物。发挥它的抗凝血和抗血栓形成的行动在和HCII通过交互。Sulodexide已被证明对纤溶系统的影响,血小板、内皮细胞、炎症和最近metalloproteases。sulodexide管理导致脂蛋白脂肪酶和已被证实的释放减少流通的脂质水平。它还显示降低全血和血浆粘度。Sulodexide与肝素的不同之处在于其口服生物利用度和较长的半衰期。还有少出血与sulodexide有关。此外,口服sulodexide不会干扰常用药物的药理学的行动。 Similar to heparin, sulodexide releases TFPI which contributes to its antithrombotic effect and anti-inflammatory properties. Sulodexide has been proven to be effective in peripheral arterial thrombosis and venous thrombosis. It is also clinically active in the treatment of venous leg ulcers and intermittent claudication. More recent data suggest that sulodexide can be used in tinnitus and in vascular vertigo. Additional studies in these indications are required. Sulodexide was generally safe and well tolerated in the clinical trials, without any severe bleeding complications. Therefore sulodexide appears to be a good treatment for all arterial and venous diseases and for the prevention of progression of disease.

DrugBank数据引用了这篇文章

药物

Sulodexide

食物相互作用

药物	交互
Sulodexide	避免与抗凝/抗血小板活动草药和补品。例子包括大蒜、生姜、越桔、丹参、吡拉西坦、银杏。